QURE — uniQure N.V.
Is QURE overbought or oversold? Here is the current MarketMoodz read.
uniQure N.V. (QURE) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $21.88. The rating moved from Overbought to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$21.88
- Last changeMoved from Overbought to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
uniQure N.V. (QURE) is a gene-therapy focused biotechnology company with platform-level upside tied to durable clinical outcomes and successful commercial execution. Financially, the firm has historically depended on partnerships and capital markets to fund development; near-term liquidity and potential dilution are material considerations. Key near-term drivers include clinical readouts, regulatory interactions, manufacturing scale-up, and any strategic partnership or acquisition interest from larger pharma; conversely, payor/reimbursement dynamics and broader market risk-off sentiment could limit upside in the coming weeks. Social and research sentiment data were not available in the input; absent strong sentiment tailwinds, price action will likely track clinical/regulatory cadence and funding news.
Key factors
- Gene therapy platform with potential for durable, one-time treatments in specialty/rare disease areas
- Limited near-term commercialization revenue; historical reliance on partnerships, milestone payments and capital markets for runway
- Regulatory and reimbursement environment for high-cost gene therapies remains uncertain but could support premium pricing if clinical durability is proven
- Potential strategic interest from large-cap pharmaceutical companies seeking to consolidate specialty franchises, creating M&A optionality
- Manufacturing and scale-up capabilities are critical — successful CMC execution would materially de-risk commercial launch potential
- Current market risk-off tone and defensive sector flows could cap near-term share appreciation despite company-specific developments
Risks
- Clinical trial setbacks or safety signals that delay approvals or reduce perceived durability of benefit
- Adverse regulatory decisions or more onerous post-marketing requirements that raise development and commercialization costs
- Reimbursement pressure from payors and Medicare/Medicaid program changes that constrain pricing and access for high-cost therapies
- Manufacturing scale-up failures or supply disruptions that hamper launch and revenue realization
- Ongoing cash burn and need for additional financing could cause dilution or unfavorable partnership terms
- Intensifying competition from other gene therapies, biologics, or emerging modalities targeting the same indications
Latest MarketMoodz coverage
- FDA Accelerated Pathway Spurs uniQure Surge, Shifts Biotech Bets2026-06-18
- FDA Signals AMT-130 Data Could Support Accelerated Approval2026-06-17
- Moderna, Capricor Lead Biotech Movers on FDA Shakeups and HOPE-3 Data2026-03-09
- FDA Defends Placebo Trial for uniQure Huntington's Gene Therapy2026-03-05
- UniQure stock slides 40% after FDA signals AMT-130 data can't support filing2026-03-02
See today's live rating, score and targets
Members see the live hourly rating for QURE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.